MedPath

No More Sleepless Nights in Perimenopause

Phase 4
Not yet recruiting
Conditions
Insomnia
Menopause
Interventions
Behavioral: Cognitive Behavioural Therapy for Insomnia (CBT-I)
Drug: Hormone Replacement Therapy (HRT)
Behavioral: Sleep Hygiene
Registration Number
NCT06497894
Lead Sponsor
Insel Gruppe AG, University Hospital Bern
Brief Summary

The goal of the clinical trial is to learn if Hormone Replacement Therapy (HRT) and Cognitive Behavioral Therapy (CBT-I) can treat insomnia in menopausal women. The main questions it aims to answer are:

* Are HRT and CBT-I effective in reducing insomnia in menopausal women?

* Are HRT and CBT-I comparable in terms of reducing insomnia severity in this population?

Researchers will compare HRT and CBT-I to an active control group, receiving sleep hygiene instructions.

Participants will:

* Complete a screening and baseline assessment

* Receive Hormone Replacement Therapy (as prescribed), Cognitive Behavioral Therapy (1/week), or sleep hygiene instructions (1/week) for 8 weeks.

* Keep a daily diary (sleep e-diary), to assess sleep-quality.

* Wear an electroencephalogram (EEG) during 6 nights (3 at baseline \& 3 post-intervention), to assess deep sleep cycles and waking episodes.

* Receive a phone call for intervention compliance

* Complete a post-intervention assessment.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
Female
Target Recruitment
54
Inclusion Criteria
  • Late menopausal transition according to Stages of Reproductive Aging criteria (STRAW+10)
  • Pittsburgh Sleep Quality Index (PSQI) score > 5
  • Insomnia Severity Index (ISI) score > 7
  • Somato-vegetative domain of the Menopause Rating Scale (MRS)-II ≥ 4 points
  • Willingness to use HRT for menopausal symptom reliefs
Exclusion Criteria
  • Other sleep-wake disorders according to DSM-5, assessed with validated questionnaires (Sleep-Health Questionnaire, Epworth Sleepiness Scale (ESS))
  • Untreated hormonal disorder
  • Obesity (BMI ≥ 30)
  • Current psychotherapy
  • Current psychopharmacological therapy including regular sleep medication
  • History of unsuccessful CBT-I
  • Psychiatric illness
  • Substance abuse (≥ 7 cigarettes/day, no more than 2 standard WHO drinks per day, other drugs)
  • Shift work
  • Long-haul flights across different time zones in the past 3 months
  • Pregnancy and lactation
  • Contraindications to HRT according to drug information (https://www.swissmedicinfo.ch/)
  • Inability to follow procedures or insufficient knowledge of project language
  • Inability to give consent

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Cognitive Behavioral Therapy for insomnia (CBT-I)Cognitive Behavioural Therapy for Insomnia (CBT-I)Participants in this experimental arm will receive cognitive behavioral therapy specifically designed to treat insomnia (CBT-I). The therapy will be delivered over 8 weekly sessions, each lasting 60 minutes. The sessions will include techniques such as sleep restriction, stimulus control, cognitive restructuring, and relaxation training. The primary goal is to improve sleep quality and reduce the severity of insomnia.
Hormone Replacement Therapy (HRT)Hormone Replacement Therapy (HRT)Participants in this experimental arm will receive hormone replacement therapy, specifically a combination of estrogen and progesterone over the course of 8 weeks. The therapy aims to alleviate menopausal symptoms, including insomnia, by addressing hormonal imbalances.
Sleep HygieneSleep HygieneParticipants in this sham comparator arm will receive sleep hygiene instructions. Instructions will be delivered over 8 weekly sessions. The instructions will provide general information about healthy sleep habits, such as food and drink choices, a regular sleep schedule, evening routine, etc. Although being widely used in daily clinical practice, sleep hygiene shows no significant effect as monotherapy in patients with an established insomnia. The sleep hygiene condition in this study is matched to CBT-I in frequency and intensity of contact.
Primary Outcome Measures
NameTimeMethod
Reduction of Insomnia SeverityWeek 10

Change from baseline in Insomnia Severity Index (ISI). The ISI is a seven-item questionnaire, asking respondents to rate the severity of sleep-related symptoms on 5-point Likert scales (Ranging between 0 = not applicable and 4 = very strong). Total values may range between 0 and 28, where 0 indicates no presence of sleep-related symptoms and 28 indicates very severe symptoms.

Secondary Outcome Measures
NameTimeMethod
Improvement in Climacteric SyndromeWeek 10

Change from baseline in Menopause Rating Scale (MRS-II) The MRS-II is an eleven-item questionnaire, asking respondents to rate the severity of climcteric syndrome-related symptoms on 5-point Likert scales (Ranging between 0 = not applicable and 4 = very strong). Total values may range between 0 and 44, where 0 indicates no presence of symptoms and 44 indicates very severe symptoms.

Changes in bio-functional ageWeek 10

Change from baseline in biofunctional status (i.e. differences between chronological age and biofunctional age).

Changes in maladaptive sleep-related cognitionsWeek 10

Change from baseline in Dysfunctional Attitudes and Beliefs about Sleep Scale (DBAS).

The DBAS is a sixteen-item questionnaire, asking respondents to rate their attitudes/beliefs about sleep on 10-point numerical rating-scales (discrete intervals), ranging between 0 (I do not agree at all) and 10 (I agree completely). Total values may range between 0 and 160, where 0 indicates no presence of dysfunctional attitudes and 160 indicates very severe levels of maladaptive sleep-related cognitions.

Trial Locations

Locations (1)

University Hospital of Bern, Department of Gynecological Endocrinology & Reproductive Medicine

🇨🇭

Bern, Switzerland

© Copyright 2025. All Rights Reserved by MedPath